glp-1 news today cardiovascular outcomes 2025 november Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices GLP-1 Agonists in Cardiovascular Diseases:

This is great news for your clients interested in weight loss drugs

References Wegovy (semaglutide) Prescribing Information Novo Nordisk FDA Drug Label Zepbound (tirzepatide) Prescribing Information Eli Lilly FDA Drug Label Saxenda (liraglutide) Prescribing Information Novo Nordisk FDA Drug Label Limitations This is not dosing advice

The expected timeline for patent expiration: The long patent timelines reflect layered intellectual property: composition-of-matter patents, formulation patents, manufacturing process patents, and dosing regimen patents

35 Similarly, in a recent study of obese individuals without diabetes, Louis et al demonstrated that tirzepatide (10 or 15 mg) resulted in significantly greater weight loss than semaglutide (1.7 or 2.4 mg) over a 72-week period

Can Ozempic, Wegovy, & Mounjaro Help with Weight Loss